Leonard Frank X
SEC CIK 1822879 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | Pres, CNS Cancers US | 461.4K | — | $13.90M | 46 | 2021-07-06 | 2026-06-30 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Transactions 46
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 16:30 | 2026-06-30 | NVCR | NovoCure Ltd | Leonard Frank X | CEO | A - Grant | $11.15 | +1,905 | 461.4K | +0.4% | +$21.2K | |
| 2026-06-05 16:28 | 2026-06-04 | NVCR | NovoCure Ltd | Leonard Frank X | CEO | S - Sale | $17.93 | -34.3K | 459.5K | -7% | -$614.6K | |
| D | 2026-03-05 | 2026-03-04 | NVCR | NovoCure Ltd | Leonard Frank X | CEO | S - Sale | $13.31 | -5,607 | 493.8K | -1% | -$74.6K |
| D | 2026-03-05 | 2026-03-03 | NVCR | NovoCure Ltd | Leonard Frank X | CEO | A - Grant | $0.00 | +150.0K | 499.4K | +43% | $0 |
| 2026-03-03 | 2026-02-28 | NVCR | NovoCure Ltd | Leonard Frank X | CEO | A - Grant | $0.00 | +18.6K | 356.6K | +6% | $0 | |
| M | 2026-03-03 | 2026-02-27+ | NVCR | NovoCure Ltd | Leonard Frank X | CEO | S - Sale | $13.59 | -17.0K | 349.4K | -5% | -$230.5K |
| 2025-11-04 | 2025-11-01 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | F - Tax | $12.81 | -966 | 347.7K | -0.3% | -$12.4K | |
| 2025-07-01 | 2025-06-30 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $15.13 | +833 | 348.7K | +0.2% | +$12.6K | |
| 2025-06-06 | 2025-06-04 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $0.00 | +179.4K | 347.9K | +107% | $0 | |
| MT | 2025-06-04 | 2025-06-02 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $17.50 | -30.2K | 168.5K | -15% | -$528.4K |
| D | 2025-03-06 | 2025-03-04 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $18.19 | +55.0K | 198.6K | +38% | +$1000.0K |
| 2025-03-04 | 2025-03-03 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $18.54 | -2,527 | 143.7K | -2% | -$46.9K | |
| MA | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15.0K | 149.0K | -9% | -$296.2K |
| M | 2025-03-03 | 2025-02-27+ | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $19.70 | -15.0K | 149.0K | -9% | -$296.2K |
| 2024-11-04 | 2024-11-01 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $15.94 | -598 | 161.2K | -0.4% | -$9,532 | |
| 2024-08-06 | 2024-06-28 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $12.24 | +1,736 | 161.8K | +1% | +$21.2K | |
| M | 2024-03-05 | 2024-03-01+ | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.02 | -2,519 | 160.1K | -2% | -$40.4K |
| D | 2024-02-29 | 2024-02-27 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | A - Grant | $16.30 | +102.2K | 164.7K | +164% | +$1.67M |
| D | 2024-02-29 | 2024-02-28 | NVCR | NovoCure Ltd | Leonard Frank X | EVP, Pres, Novocure Oncology | S - Sale | $16.14 | -2,078 | 162.6K | -1% | -$33.5K |
| M | 2023-03-07 | 2023-03-03+ | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.55 | -13.6K | 63.5K | -18% | -$1.03M |
| 2023-03-06 | 2023-03-03 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +11.8K | 70.0K | +20% | $0 | |
| M | 2023-03-06 | 2023-03-02+ | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.95 | -2,903 | 58.1K | -5% | -$223.4K |
| M | 2023-03-03 | 2023-03-02 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $75.37 | -4,107 | 59.0K | -7% | -$309.6K |
| D | 2023-03-02 | 2023-02-28 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +18.6K | 64.8K | +40% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.36 | -1,684 | 63.1K | -3% | -$128.6K |
| DM | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale+OE | $112.25 | -39.5K | 47.2K | -46% | -$4.43M |
| DM | 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | M - OptEx | $15.39 | +35.2K | 53.3K | +194% | +$541.7K |
| D | 2022-11-03 | 2022-11-01 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | A - Grant | $0.00 | +6,830 | 50.5K | +16% | $0 |
| 2022-10-17 | 2022-10-13 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $76.01 | -6,754 | 43.6K | -13% | -$513.4K | |
| 2022-10-07 | 2022-10-06 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $84.37 | -6,754 | 50.4K | -12% | -$569.8K | |
| 2022-09-30 | 2022-09-29 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.35 | -6,754 | 57.1K | -11% | -$522.4K | |
| 2022-09-26 | 2022-09-22 | NVCR | NovoCure Ltd | Leonard Frank X | Pres, CNS Cancers US | S - Sale | $77.00 | -6,754 | 63.9K | -10% | -$520.1K | |
| DM | 2022-09-19 | 2022-09-15 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale+OE | $88.52 | -12.3K | 70.6K | -15% | -$1.09M |
| D | 2022-09-19 | 2022-09-15 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | M - OptEx | $7.15 | +5,517 | 82.9K | +7% | +$39.4K |
| A | 2022-09-13 | 2022-09-08 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $81.48 | -6,754 | 77.4K | -8% | -$550.3K |
| 2022-09-12 | 2022-09-09 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $88.00 | -1,863 | 84.2K | -2% | -$163.9K | |
| 2022-09-07 | 2022-09-06 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $78.57 | -1,384 | 86.0K | -2% | -$108.7K | |
| M | 2022-09-06 | 2022-09-01+ | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $77.50 | -14.8K | 88.8K | -14% | -$1.15M |
| 2022-08-03 | 2022-08-02 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $69.66 | -414 | 102.2K | -0.4% | -$28.8K | |
| 2022-07-07 | 2022-07-05 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | A - Grant | $59.08 | +312 | 102.6K | +0.3% | +$18.4K | |
| 2022-03-09 | 2022-03-08 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $70.10 | -744 | 102.3K | -0.7% | -$52.2K | |
| D | 2022-03-07 | 2022-03-03 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | A - Grant | $0.00 | +17.4K | 104.5K | +20% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $72.97 | -1,485 | 103.6K | -1% | -$108.4K |
| 2021-09-07 | 2021-09-02 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $138.23 | -540 | 87.2K | -0.6% | -$74.6K | |
| M | 2021-08-04 | 2021-08-02+ | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | S - Sale | $149.40 | -1,041 | 89.2K | -1% | -$155.5K |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development Off | A - Grant | $137.12 | +154 | 90.2K | +0.2% | +$21.1K |
Purchase Sale Sale after option exercise All abbreviations